Drug Trial Radar · NCT07905560
A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
138
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jan 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Superluminal Medicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1, first-in-human study will evaluate the safety and tolerability of SUN-0864, how the body processes SUN-0864, and how SUN-0864 affects the body in healthy adults and otherwise healthy adults who are overweight or obese. The study includes four parts: Part 1, a single ascending dose (SAD) assessment in healthy adults; Part 2, a 28-day multiple ascending dose (MAD) assessment in overweight or obese adults; Part 3, a 12-week multiple-dose assessment in overweight or obese adults; and Part 4, an assessment comparing two formulations and evaluating the effect of food on SUN-0864 in healthy adults. Approximately 128 to 138 subjects will be randomized into this study. Dose escalation and selection of dose levels for later study parts will be guided by review of safety, tolerability, and available study data by a Safety Review Committee.
Conditions
- Healthy Participants
Interventions
SUN-0864 or placeboDrug
Single ascending dose of SUN-0864 or placebo (oral)
SUN-0864 or placeboDrug
Multiple ascending dose of SUN-0864 or placebo (oral)
SUN-0864 or placeboDrug
Multiple doses of SUN-0864 or placebo (oral)
SUN-0864 (Formulation 1) or SUN-0864 (Formulation 2)Drug
SUN-0864 (oral) Dose level Formulation 1 (fasted) and Formulation 2 (fasted and fed)
PlaceboDrug
Placebo (oral)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) (Treatment-Related TEAE) (Part 1)Time frame: Baseline up to Follow-Up (From Day -28 (Screening) to Day 37 (FUP visit)
- Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) (Treatment-Related TEAE) (Part 2)Time frame: From Day -28 (Screening) to Day 60 (FUP visit)
- Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) (Treatment-Related TEAE) (Part 3)Time frame: From Day -28 (Screening) to Day 119 (FUP visit)
- Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) (Treatment-Related TEAE) (Part 4)Time frame: From Day -28 (Screening) to Day 37 (FUP visit)
- Cmax measurement of SUN-0864 in Part 4Time frame: up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3.
- Tmax measurement of SUN-0864 in Part 4Time frame: up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3.
- t1/2 measurement of SUN-0864 in Part 4Time frame: up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3.
- AUClast measurement of SUN-0864 in Part 4Time frame: up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3.
- AUCinf measurement of SUN-0864 in Part 4Time frame: up to 48 hours post-dose. Daily from Day 1 (Predose) to Day 3.
- AUC24 measurement of SUN-0864 in Part 4Time frame: up to 24 hours post-dose. Daily from Day 1 (Predose) to Day 3.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.